“为最大多数病患而创新” 荃信生物让生物药“飞入寻常百姓家”

Core Viewpoint - The company, Qianxin Biotech, has established itself as a leading player in the field of biopharmaceuticals, particularly focusing on autoimmune diseases, with a commitment to making high-quality therapies accessible to the general public [1][2]. Group 1: Company Overview - Qianxin Biotech was founded by Qiu Jiwan, who has decades of experience in biopharmaceutical research and development, and has grown into a national high-tech enterprise with over a hundred domestic and international patents [1]. - The company's mission emphasizes scientific innovation and the provision of affordable, high-quality therapies, aiming to meet the needs of ordinary patients [1][2]. Group 2: Product Development Strategy - The company focuses on a single domain of autoimmune diseases to concentrate resources and avoid distraction, capitalizing on the large patient base and diverse disease types within this field [1][2]. - Qianxin Biotech has successfully launched QX001S (brand name: Sailixin), the first approved biosimilar of ustekinumab in China, addressing the urgent needs of psoriasis patients [1][2]. Group 3: Innovation and Market Position - The company adopts a "combination innovation" approach, developing both biosimilars to lower drug costs and innovative drugs to overcome treatment bottlenecks, thereby making medications more accessible [2]. - Qianxin Biotech's pipeline includes QX002N and QX005N, targeting different autoimmune diseases with a differentiated strategy to build competitive advantages [3][4]. Group 4: Global Expansion and Partnerships - Recently, Qianxin Biotech entered a global exclusive collaboration with Roche for its long-acting dual antibody QX031N, receiving an upfront payment of $75 million and potential milestone payments of up to $995 million [5]. - The company aims to establish a global presence by entering overseas markets early and leveraging partnerships to accelerate product development [5]. - Qianxin Biotech's strategy includes building a global cooperation network and exploring various collaboration models to enhance its international footprint [5].